CORDEN PHARMA – Oligonucleotide development trends: Growing Interest in oncology therapies
Click HERE to download the PDF version
Matthieu Giraud PhD
Director, Global Peptides, Oligonucleotides, Lipids & Carbohydrates Platforms
Advances in drug delivery, new technology, and a deeper understanding of oligonucleotides have led to escalating interest in developing these promising compounds. Research on these chemically synthesized compounds began about 50 years ago to address a wide range of conditions considered “undruggable” with small-molecule therapeutics. While development, delivery and regulatory challenges along with trial failures discouraged many developers, there has been a renewal of interest in oligonucleotides since early 2014, according to the numbers of NCEs entering clinical Phase I.
CLINICAL TRIALS: DELAYED PROGRESS
Today, about 170 ...